From scarcity to scale: Nepal’s bid to become Global South’s healthcare disruptor

Nepal stands at a critical juncture, poised to redefine its role in global healthcare by embracing biodigital solutions and addressing the persistent challenges within its pharmaceutical and biotechnology sectors. The nation's ambition to transition from a Least Developed Country (LDC) status is intrinsically linked to its capacity to innovate and deliver accessible, high-quality healthcare, particularly through the strategic use of data and digital technologies.

The vision is ambitious: to harness individual health data for personalized theranostics and to create a system where sharing such information can alleviate treatment costs. This forward-thinking approach is supported by a government eager to implement change and significant interest from both regional and international partners. Nepal has developed numerous strategy papers, policies, and guidelines for digital health, with various hospitals actively engaged in digitalization efforts.

However, the path forward is not without its obstacles. Nepal's biotechnology sector remains nascent, despite having access to WTO's TRIPS facilitations. The country largely depends on imported active pharmaceutical ingredients, and the quality of these imports is frequently questioned. Unlike Bangladesh, which has achieved near self-sufficiency in pharmaceutical production and is exporting advanced drugs, Nepal lags significantly in this domain. This reliance on external sources highlights a vulnerability that needs urgent attention.

The Kathmandu Post recognizes that while digital health initiatives have seen some traction, they often suffer from 'pilot fatigue' and data siloes. These fragmented solutions, often funded by donors with shifting priorities, hinder the creation of compounding gains for policymakers and patients alike. For Nepal to truly emerge as a healthcare disruptor, a strategic, long-term state-led gambit is essential, particularly for developing the harder assets needed for leadership in biotech, a feat achieved by nations like Malaysia and Cuba through sustained national will.